Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a)

Atherosclerosis Supplements

Volumn 18, Issue , 2015, Pages 187-193

  Poller, Wolfram C ^b   Dreger, Henryk ^b   Morgera, Stanislao ^c   Berger, Axel ^a   Flessenkämper, Ingo ^a   Enke Melzer, Kathrin ^a  

^a HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Schwerpunktpraxis für Nieren und Hochdruckkrankheiten Berlin   (Germany)

Author keywords

Hyperlipoproteinemia(a); Lipoprotein apheresis; Lipoprotein(a); Peripheral artery disease

Indexed keywords

LIPOPROTEIN A; BIOLOGICAL MARKER;

ADULT; ANKLE BRACHIAL INDEX; APHERESIS; ARTICLE; CLINICAL ARTICLE; CRITICAL LIMB ISCHEMIA; FEMALE; FUNCTIONAL STATUS; HUMAN; HYPERLIPOPROTEINEMIA; LIPOPROTEIN APHERESIS; LIPOPROTEIN BLOOD LEVEL; MALE; MICROCIRCULATION; OBSERVATIONAL STUDY; OXYGEN SUPPLY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REVASCULARIZATION; TRANSCUTANEOUS OXYGEN MONITORING; VISUAL ANALOG SCALE; WALKING; BLOOD; COMPLICATION; CONVALESCENCE; EXERCISE TEST; EXERCISE TOLERANCE; GERMANY; HEMODYNAMICS; HYPERLIPOPROTEINEMIAS; MIDDLE AGED; PAIN MEASUREMENT; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE; PROCEDURES; REGISTER; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ANKLE BRACHIAL INDEX; BIOMARKERS; BLOOD COMPONENT REMOVAL; BLOOD GAS MONITORING, TRANSCUTANEOUS; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; GERMANY; HEMODYNAMICS; HUMANS; HYPERLIPOPROTEINEMIAS; LIPOPROTEIN(A); MALE; MICROCIRCULATION; MIDDLE AGED; PAIN MEASUREMENT; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; REGISTRIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928888992     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2015.02.032     Document Type: Article

References (29)

1. Nordestgaard B.G., Chapman M.J., Ray K., Borén J., Andreotti F., Watts G.F., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853.
2. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., Nordestgaard B.G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301:2331-2339.
3. Erqou S., Kaptoge S., Perry P.L., Di Angelantonio E., Thompson A., White I.R., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423.
4. Clarke R., Peden J.F., Hopewell J.C., Kyriakou T., Goel A., Heath S.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361:2518-2528.
5. Hoover-Plow J., Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 2012, 62:479-491.
6. Rader D.J., Cain W., Ikewaki K., Talley G., Zech L.A., Usher D., et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994, 93:2758-2763.
7. Koschinsky M.L., Marcovina S.M. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 2004, 15:167-174.
8. McLean J.W., Tomlinson J.E., Kuang W.J., Eaton D.L., Chen E.Y., Fless G.M., et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987, 330:132-137.
9. Sotiriou S.N., Orlova V., Al-Fakhri N., Ihanus E., Economopoulou M., Isermann B., et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. Faseb J 2006, 20:559-561.
10. Tsimikas S., Witztum J.L. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 2008, 19:369-377.
11. Ichikawa T., Unoki H., Sun H., Shimoyamada H., Marcovina S., Shikama H., et al. Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits. Am J Pathol 2002, 160:227-236.
12. Kamstrup P.R. Lipoprotein(a) and ischemic heart disease - a causal association? A review. Atherosclerosis 2010, 211:15-23.
13. Gurdasani D., Sjouke B., Tsimikas S., Hovingh G.K., Luben R.N., Wainwright N.W., et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2012, 32:3058-3065.
14. Leebmann J., Roeseler E., Julius U., Heigl F., Spitthoever R., Heutling D., et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013, 128:2567-2576.
15. Jaeger B.R., Richter Y., Nagel D., Heigl F., Vogt A., Roeseler E., et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009, 6:229-239.
16. Schettler V., Neumann C.L., Hulpke-Wette M., Hagenah G.C., Schulz E.G., Wieland E. Current view: indications for extracorporeal lipid apheresis treatment. Clin Res Cardiol Suppl 2012, 7:15-19.
17. German Federal Ministry of Health Publication of a decision of Federal Joint Committee on apheresis for isolated Lp(a)-elevation with progressive cardiovascular disease. Trans Ger Fed Ministries (bAnz) 2008, 138:3321.
18. Kitabatake A., Sato H., Hori M., Kamada T., Kubori S., Hoki N., et al. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group. Clin Ther 1994, 16:416-428.
19. Leitinger N., Pirich C., Blazek I., Endler G., Sinzinger H. Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment. Atherosclerosis 1996, 126:305-312.
20. Julius U., Siegert G., Gromeier S. Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system. Int J Artif Organs 2000, 23:199-206.
21. Wang Y., Blessing F., Walli A.K., Uberfuhr P., Fraunberger P., Seidel D. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004, 175:145-150.
22. Parhofer K.G. Lipoprotein(a): medical treatment options for an elusive molecule. Curr Pharm Des 2011, 17:871-876.
23. Gouni-Berthold I., Berthold H.K. Antisense oligonucleotides for the treatment of dyslipidemia. Curr Pharm Des 2011, 17:950-960.
24. Cannon C.P., Shah S., Dansky H., Davidson M., Brinton E.A., Gotto A.M., et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010, 363:2406-2415.
25. McKenney J.M., Koren M.J., Kereiakes D.J., Hanotin C., Ferrand A.C., Stein E.A., et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012, 59:2344-2353.
26. Berthold H.K., Laudes M., Krone W., Gouni-Berthold I. Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans. PLoS One 2011, 6:e24719.
27. Stefanutti C., Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl 2013, 14:19-27.
28. Laschkolnig A., Kollerits B., Lamina C., Meisinger C., Rantner B., Stadler M., et al. Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res 2014, 103(1):28-36.
29. Safarova M., Ezhov M., Afanasieva O., Matchin Y.G., Atanesyan R.V., Adamova I.Y., et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 2013, 14:93-99.